Go to deals
Healthcare

Chirana T. Injecta, a.s. has acquired Chirmax, s.r.o.

Chirana T. Injecta, a.s. has acquired a 100% stake in Chirmax, s.r.o., the Czech manufacturer of surgical suture material, for an undisclosed consideration.

Chirana T. Injecta, a.s. is a manufacturer of disposable medical devices.

Oaklins' team in the Czech Republic acted as financial advisor to the buyer in this transaction.

Parties

Talk to the deal team

Vladimír Jaros

Principal
Prague, Czech Republic
Oaklins WOOD & Co.

Michal Staron

Associate Partner
Bratislava, Slovakia
Oaklins WOOD & Co.

Related deals

Bayer AG has entered into a takeover agreement with Cara Care
Healthcare | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Learn more
Saideep Healthcare and Research has raised equity
Healthcare

Saideep Healthcare and Research has raised equity

Saideep Healthcare and Research Private Limited has successfully completed a fundraising. This funding will help Saideep become a leading healthcare brand, offering advanced specialties across the region. The funds from this collaboration will be used to diversify into new and complex specialties, expand infrastructure and meet the growing demand for high-quality healthcare services in Western India.

Learn more
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
Healthcare

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.

Learn more